NGEN-Enzy LP
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$22M
Investors
7
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
NGEN-Enzy LP is a Delaware limited partnership that first filed a Form D on December 27, 2023 and most recently amended it on September 3, 2024, describing itself as a private equity fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers pooled investment fund interests. NGEN-Enzy LP reported $21,554,508 sold from 7 investors in an offering of indefinite size as of the Form D filed September 3, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is C/O Ngen Enzymedica LLC, 775 Park Avenue, #7d, New York, NY 10021.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
3
latest Sep 3, 2024
Critical / warning
0 / 0
2 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
lapsed
Latest event First sale · Sep 3, 2024
SEC.govInvestor
- 3 filing events with values and deltas, latest 2024-09-03, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
NGEN Enzymedica LLC
Director · New York, NY
General Partner of the Applicant
Shay Murphy
Executive Officer · New York, NY
Member of the General Partner
Peter Grubstein
Executive Officer · New York, NY
Member of the General Partner
Rosemary Ripley
Executive Officer · New York, NY
Member of the General Partner
Questions About NGEN-Enzy LP
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is NGEN-Enzy LP?
NGEN-Enzy LP is a Delaware limited partnership that filed a Form D with the SEC on September 3, 2024 as a private equity fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.
Is NGEN-Enzy LP legit?
AltStreet does not rate legitimacy; it reports the public record. NGEN-Enzy LP filed a Form D with the SEC on September 3, 2024 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $21,554,508 sold to 7 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is NGEN-Enzy LP registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that NGEN-Enzy LP claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has NGEN-Enzy LP raised?
NGEN-Enzy LP reported $21,554,508 sold from 7 investors in an offering of indefinite size as of the Form D filed September 3, 2024.
Who can invest in NGEN-Enzy LP?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in NGEN-Enzy LP?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling NGEN-Enzy LP and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind NGEN-Enzy LP?
The Form D lists 4 related persons: NGEN Enzymedica LLC, director (General Partner of the Applicant); Shay Murphy, executive officer (Member of the General Partner); Peter Grubstein, executive officer (Member of the General Partner); Rosemary Ripley, executive officer (Member of the General Partner). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is NGEN-Enzy LP located?
The issuer's address on its SEC filings is C/O Ngen Enzymedica LLC, 775 Park Avenue, #7d, New York, NY 10021. Its phone number of record is 212.450.9704. It is organized under the laws of Delaware.
How long is the NGEN-Enzy LP offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.
How large is NGEN-Enzy LP?
The issuer declined to disclose its revenue range on the Form D, which the form permits.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
